share_log

藥明康德：翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

Hong Kong Stock Exchange ·  Apr 17 04:45
Summary by Moomoo AI
無錫藥明康德新藥開發股份有限公司於2024年3月11日至4月17日期間，進行了多次A股股份回購。根據公司提交的翌日披露報表，該公司在上述期間內共回購了數百萬股A股，每次回購的股份數目及發生變動的日期均有詳細記錄。回購價格與市場價格相比，呈現出不同程度的折讓或溢價。此舉動是根據香港聯合交易所有限公司證券上市規則的要求進行的，並且公司已確認所有交易均按照當地規則進行。藥明康德的此次股份回購行動可能對公司股價及股東權益產生影響。
無錫藥明康德新藥開發股份有限公司於2024年3月11日至4月17日期間，進行了多次A股股份回購。根據公司提交的翌日披露報表，該公司在上述期間內共回購了數百萬股A股，每次回購的股份數目及發生變動的日期均有詳細記錄。回購價格與市場價格相比，呈現出不同程度的折讓或溢價。此舉動是根據香港聯合交易所有限公司證券上市規則的要求進行的，並且公司已確認所有交易均按照當地規則進行。藥明康德的此次股份回購行動可能對公司股價及股東權益產生影響。
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted multiple share repurchases of A shares from March 11 to April 17, 2024. According to the Company's Next Day Disclosure Report, the Company repurchased a total of millions of shares of Class A during the above period, with detailed records of the number of shares repurchased and the date of the change. The repurchase price presents a different degree of discount or premium compared to the market price. The move is in accordance with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited and the Company has confirmed that all transactions are conducted in accordance with local rules. THIS SHARE REPURCHASE BY YAKMING KAND MAY HAVE AN IMPACT ON THE COMPANY'S SHARE PRICE AND SHAREHOLDERS' EQUITY.
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted multiple share repurchases of A shares from March 11 to April 17, 2024. According to the Company's Next Day Disclosure Report, the Company repurchased a total of millions of shares of Class A during the above period, with detailed records of the number of shares repurchased and the date of the change. The repurchase price presents a different degree of discount or premium compared to the market price. The move is in accordance with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited and the Company has confirmed that all transactions are conducted in accordance with local rules. THIS SHARE REPURCHASE BY YAKMING KAND MAY HAVE AN IMPACT ON THE COMPANY'S SHARE PRICE AND SHAREHOLDERS' EQUITY.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more